GeneChem is a manager of focused biotechnology venture capital funds.
We have over $350M in assets distributed over four funds: GeneChem Technologies, GeneChem Therapeutics, Agechem and AmorChem. Since 1997, GeneChem has been active in investing
in companies involved in drug discovery and development. Together, we have invested in over 60 companies located in the US, Canada and Europe. Today, GeneChem has established itself as a leader in the management of focused biotech funds.
At GeneChem, we believe a successful deal combines innovative science, insightful management and collaborative investor syndicate.
GeneChem is a manager of focused venture capital funds. Since 1997, we have been involved in the launching of companies and in the management of their growth and liquidity events.
GeneChem has been part of investment syndicates which included a wide breadth of marquee international investors as well as smaller local players. The team has knowledge and expertise in various fields of science including biochemistry, chemistry, immunology, oncology, virology, bacteriology, analgesia, ophthalmology and human genetics.
We have invested at the very early stages of start-ups, where hands-on management is required, and also at the later stages such as mezzanine rounds and private placements in public entities. The team's experience is broad and deep-reaching within the biotech investment sector.
1, Westmount Square
Montreal, QC H3Z 2P9
Mr. Louis P. Lacasse MBA - President and General Partner
Dr. Elizabeth Douville Ph.D. - General Partner
Dr. Martial Lacroix Ph.D. - General Partner